Fenwick represented Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation CRISPR-based and other novel gene editing tools, in a multi-year strategic research and development collaboration with Moderna Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines.
Under the terms of the collaboration, Metagenomi and Moderna will advance a series of in vivo gene editing therapeutics against undisclosed targets. Metagenomi will utilize its vast toolbox of gene editing systems in combination with Moderna’s mRNA platform, as well as lipid nanoparticle (LNP) delivery technologies, to deliver next-generation therapies for genetic diseases. More information about the collaboration can be obtained from Metagenomi’s announcement.
The Fenwick team included life sciences partners Jake Handy and Matt Rossiter; and tax partner Julia Ushakova-Stein and associate Ariel Love.